HIRA to review metformin+SGLT2+DPP4 reimb at last
By Lee, Tak-Sun | translator Alice Kang
22.06.14 14:42:55
가나다라
0
Its fiscal impact analysis to be conducted after reimbursement standard review…will the 6 year-long discussions finally come to an end
Reimbursement of 3-drug SGLT-2+metformin+TZD and 2-drug combo using sulfonylurea or insulin also to be considered
▲Ae-Ryun Kim, Deputy Minister of HIRA
The Health Insurance Review and Assessment Service entered the final steps of its reimbursement review for a 3-drug combination therapy that contains metformin, an SLGT-2 inhibitor, and a DPP-4 inhibitor. Reimbursement of the combined use of SGLT-2 and DPP-4 class oral antidiabetic drugs had been continuously raised as an issue by academic societies including the Korean Diabetes Association as well as the pharmaceutical industry since 2016.
Therefore, whether HIRA will newly establish a reimbursement standard and finally bring an end to this discussion is gaining industry attention.
At the press conference with the Korea Special Press Association on the 14th, Deputy Min
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)